NHS (Neuberger Berman High Yield Strategies Fund) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NHS Neuberger Berman High Yield Strategies Fund Inc NHS
44 GF Score
Price $6.20
GF Value $7.23
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neuberger Berman High Yield Strategies Fund Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Neuberger Berman High Yield Strategies Fund Valuation Rank Related Terms

NHS
44GF Score
Neuberger Berman High Yield Strategies Fund Inc NHS
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Neuberger Berman High Yield Strategies Fund (NHS) Overvalued in 2026?

Based on GuruFocus' analysis, Neuberger Berman High Yield Strategies Fund stock appears to be undervalued. The current stock price of $6.20 is trading 14.2% below its estimated GF Value™ of $7.23. GuruFocus considers Neuberger Berman High Yield Strategies Fund to be Modestly Undervalued.

Key valuation signals for NHS:

  • Valuation Rank:
  • GF Value™: $7.23 vs. price of $6.20 (14.2% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the NHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuberger Berman High Yield Strategies Fund Business Description

Address c/o Neuberger Berman Investment Advisers LLC, 1290 Avenue of the Americas, New York, NY, USA, 10104-0002
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.
44GF Score

Get the complete analysis for NHS

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.20
Price
$7.23
GF Value